JP2006502143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502143A5 JP2006502143A5 JP2004529871A JP2004529871A JP2006502143A5 JP 2006502143 A5 JP2006502143 A5 JP 2006502143A5 JP 2004529871 A JP2004529871 A JP 2004529871A JP 2004529871 A JP2004529871 A JP 2004529871A JP 2006502143 A5 JP2006502143 A5 JP 2006502143A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- halogen
- group
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 6
- -1 (1) tetrazolyl Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 21
- 238000000034 method Methods 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40590802P | 2002-08-26 | 2002-08-26 | |
| PCT/US2003/026377 WO2004018386A2 (en) | 2002-08-26 | 2003-08-22 | Acetophenone potentiators of metabotropic glutamate receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502143A JP2006502143A (ja) | 2006-01-19 |
| JP2006502143A5 true JP2006502143A5 (enExample) | 2006-10-05 |
Family
ID=31946942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004529871A Withdrawn JP2006502143A (ja) | 2002-08-26 | 2003-08-22 | 向代謝型グルタミン酸受容体のアセトフェノン増強因子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050288346A1 (enExample) |
| EP (1) | EP1556038A2 (enExample) |
| JP (1) | JP2006502143A (enExample) |
| AU (1) | AU2003262805A1 (enExample) |
| CA (1) | CA2495756A1 (enExample) |
| WO (1) | WO2004018386A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA009902B1 (ru) | 2004-02-13 | 2008-04-28 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Модуляторы рецепторов андрогенов |
| JP2007532621A (ja) | 2004-04-13 | 2007-11-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲンモジュレータ |
| BRPI0509980A (pt) * | 2004-04-22 | 2007-10-16 | Warner Lambert Co | moduladores de androgênio |
| MXPA06015169A (es) | 2004-07-08 | 2007-08-21 | Warner Lambert Co | Moduladores de androgenos. |
| CN1993326A (zh) * | 2004-07-30 | 2007-07-04 | 默克公司 | 代谢型谷氨酸受体的杂环苯乙酮增效剂 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| ATE543807T1 (de) * | 2004-11-22 | 2012-02-15 | Lilly Co Eli | Verstärker von glutamat-rezeptoren |
| AU2011226942B2 (en) * | 2004-11-22 | 2012-06-28 | Eli Lilly And Company | Potentiators of glutamate receptors |
| CA2598531A1 (en) * | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| AR065622A1 (es) * | 2007-03-07 | 2009-06-17 | Ortho Mcneil Janssen Pharm | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| BRPI0816970A2 (pt) * | 2007-09-14 | 2015-03-24 | Ortho Mcneil Janssen Pharm | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas |
| TW201006801A (en) * | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| US10099993B2 (en) | 2014-04-06 | 2018-10-16 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof |
| CA3123937A1 (en) * | 2018-12-17 | 2020-06-25 | 6th Wave Innovations Corp. | Lithium extraction with crown ethers |
| US20250179000A1 (en) * | 2021-12-23 | 2025-06-05 | Sanford Burnham Prebys Medical Discovery Institute | Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof |
| EP4299124A1 (en) | 2022-06-30 | 2024-01-03 | Universite De Montpellier | Anti-mglur2 nanobodies for use as biomolecule transporter |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2058785B (en) * | 1979-09-05 | 1983-05-25 | Glaxo Group Ltd | Phenol derivatives |
| DE3116079A1 (de) * | 1981-04-23 | 1982-11-11 | Robert Bosch Gmbh, 7000 Stuttgart | Pruefsystem |
| US4567201A (en) * | 1981-11-25 | 1986-01-28 | Takeda Chemical Industries, Ltd. | Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof |
| FI833770A7 (fi) * | 1982-10-21 | 1984-04-22 | Lilly Industries Ltd | Orgaanisia yhdisteitä ja niiden käyttö lääkkeinä. |
| US4820867A (en) * | 1983-04-21 | 1989-04-11 | Merck Frosst Canada, Inc. | Phenoxypropoxy halophenylacetic acids as leukotriene antagonists |
| GB8318889D0 (en) * | 1983-07-13 | 1983-08-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| US4663332A (en) * | 1985-10-10 | 1987-05-05 | Hoffman-La Roche Inc. | 5-substituted N-alkylated tetrazoles |
| US6020382A (en) * | 1996-02-02 | 2000-02-01 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
-
2003
- 2003-08-22 JP JP2004529871A patent/JP2006502143A/ja not_active Withdrawn
- 2003-08-22 AU AU2003262805A patent/AU2003262805A1/en not_active Abandoned
- 2003-08-22 WO PCT/US2003/026377 patent/WO2004018386A2/en not_active Ceased
- 2003-08-22 EP EP03793309A patent/EP1556038A2/en not_active Withdrawn
- 2003-08-22 US US10/524,704 patent/US20050288346A1/en not_active Abandoned
- 2003-08-22 CA CA002495756A patent/CA2495756A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526999A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2009519243A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| JP2011515482A5 (enExample) | ||
| JP2009536660A5 (enExample) | ||
| JP2007505877A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| US20180186770A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| JP2010510243A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2011529918A5 (enExample) | ||
| CN107848952B (zh) | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
| RU2010126056A (ru) | Органические соединения | |
| JP2013525490A5 (enExample) | ||
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| JP2005536519A5 (enExample) | ||
| CA2554550A1 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| JP2004517130A5 (enExample) | ||
| JP2010514734A5 (enExample) | ||
| JP2010514733A5 (enExample) | ||
| JP2007532649A5 (enExample) |